HSA Singapore SG-eCTD Version 1.1 Package Update
The Health Sciences Authority (HSA) of Singapore has released an updated package for SG-eCTD version 1.1. This update pertains to the electronic Common Technical Document submission format used for regulatory filings.
HSA Singapore: Adverse Effects from Banned Medicinal Products
HSA Singapore has issued a notice regarding adverse effects reported after consumers took banned medicinal products. The agency is highlighting the risks associated with using unapproved health products and urges consumers to exercise caution.
HSA Singapore New Drug Approvals - January 2026
HSA Singapore announced new drug approvals for January 2026. This notice serves to inform stakeholders of the latest additions to the approved drug list.
Keynote on Longevity Innovation, Regulation, and Collaboration
The Health Sciences Authority (HSA) of Singapore has published the text of a keynote address discussing innovation in longevity, the regulatory landscape, and the importance of collaboration. The speech highlights the evolving field of longevity and the need for regulatory frameworks to keep pace with scientific advancements.
NARSskin Night Treatment Recalled Due to Sudan IV Detection
The Health Sciences Authority (HSA) of Singapore has initiated a retail-level recall for all batches of NARSskin light reflecting restorative night treatment. The product was found to contain Sudan IV, a substance not permitted in cosmetic products, during a quality surveillance program. Local company Shiseido Singapore Co. (Pte) Limited is instructed to stop supplying the product and return existing stocks.
MHRA Class 2 Medicines Recall: Hibiwash 500ml due to Microbial Contamination
The MHRA has issued a Class 2 Medicines Recall for Hibiwash 500ml manufactured by Regent Medical Limited / Mölnlycke Health Care due to microbial contamination. Specific batches are affected, and the recall is being conducted to protect public health.
WHO and Partners Launch Digital Health Wallets for ASEAN
The WHO, in partnership with the Temasek Foundation, has launched a three-year initiative to help ASEAN Member States transition from paper-based health records to digital health wallets. This program aims to strengthen national health systems and improve continuity of care by providing trusted, portable access to essential health information.
ANSM Surveillance of Ixchiq Vaccine Adverse Effects
The French National Agency for the Safety of Medicines and Health Products (ANSM) is continuing its surveillance of adverse effects associated with the Ixchiq vaccine, used for chikungunya prevention. This notice serves to inform the public and healthcare professionals about ongoing monitoring activities.
EMA CHMP Meeting Agenda March 2026
The European Medicines Agency (EMA) has published the agenda for the Committee for Medicinal Products for Human Use (CHMP) meeting scheduled for March 23-26, 2026. The agenda outlines discussions on various medicinal products, including initial applications, oral explanations for pre-authorisation, re-examination, and post-authorisation procedures.
EMA CHMP Meeting Agenda March 2026
The European Medicines Agency (EMA) has published the agenda for the Committee for Medicinal Products for Human Use (CHMP) meeting scheduled for March 23-26, 2026. The agenda outlines 23 procedures, including annual reassessments and Periodic Safety Update Reports (PSURs), for review by the committee.
ANSM Safety Alert: Space Plus Perfusor Syringe Pump by B Braun
The French National Agency for the Safety of Medicines and Health Products (ANSM) has issued a safety alert regarding the Space Plus Perfusor syringe pump manufactured by B Braun Melsungen AG. This alert informs healthcare facilities and pharmacies about a safety action implemented by the manufacturer.
ANSM Safety Recall: Quadripod Cane 548 bis HMS-Vilgo
The French National Agency for Medicines and Health Products Safety (ANSM) has announced a safety recall (R2608257) for the Quadripod cane model 548 bis HMS-Vilgo, initiated by the manufacturer HMS-Vilgo. The recall is directed at pharmacies, healthcare facilities, and home health providers.
ANSM Safety Information: Thoraflex Hybrid Thoracic Aorta Prosthesis
The French National Agency for Medicines and Health Products Safety (ANSM) has issued a safety alert regarding the Thoraflex Hybrid thoracic aorta prosthesis manufactured by Vascutek Ltd. Healthcare providers have been notified of a safety action implemented by the manufacturer.
ANSM Safety Information: Vitros MicroSlide Mg Reagent
The French ANSM has issued a safety alert regarding the Vitros MicroSlide Mg reagent from QuidelOrtho. Affected users have been notified directly by the company, and the action is registered under ANSM number R2607971. This notice provides information and a link to the company's safety communication.
DEA Seizes 215lbs Meth, Sentences Drug Trafficking Leader
The DEA announced the seizure of over 215 pounds of methamphetamine and the sentencing of Cesar Delfin-Cervantes to nearly 16 years in prison. Delfin-Cervantes was identified as a leader in a multi-state and international drug trafficking organization.
FDA Advisory Letters Notify Firms of Federal Law Violations
The FDA's Center for Veterinary Medicine is posting Untitled Letters on its website to inform the public about firms violating federal law. These letters notify firms of violations that do not meet the threshold for a Warning Letter but still require correction.
FDA Untitled Letters to Pharmaceutical Companies
The FDA's CDER Freedom of Information Office has published a list of 34 untitled letters issued to pharmaceutical companies between February 2026 and September 2025. These letters address promotional communications for various prescription drugs, indicating potential violations of FDA regulations regarding drug advertising and promotion.
FDA Untitled Letters Issued 2011-2018
The FDA has posted a collection of 83 untitled letters issued between 2011 and 2018 by its Center for Food Safety and Applied Nutrition (CFSAN). These letters address violations related to manufacturing controls or labeling that did not meet the threshold for a Warning Letter.
FDA CBER Issues Untitled Letters for Violations
The FDA's Center for Biologics Evaluation and Research (CBER) issues untitled letters to regulated industries for violations that do not meet the threshold for a Warning Letter. These letters address issues found in advertising and promotional labeling, bioresearch monitoring, and internet surveillance.
FDA K253532: TruSPECT Processing Station Submission
The FDA has published a 510(k) premarket notification submission for the TruSPECT Processing Station, identified by K253532. This notification indicates a new device is being reviewed or has been cleared by the FDA.
FDA PeekMed Radiology Software 510(k) Notification
The FDA has published a 510(k) premarket notification for PeekMed web radiology software. This notification indicates that the software has met the requirements for market entry, allowing it to be used by healthcare providers.
FDA SKOUT system K253664 Medical Device Notification
The FDA has published a 510(k) premarket notification for the SKOUT system (K253664). This notification indicates a new medical device has been cleared for market. Further details on the device's specific function and intended use are available through the provided FDA database link.
FDA 510(k) Premarket Notification - AIR Recon DL
The FDA has published a 510(k) premarket notification for the AIR Recon DL, a device from GE Medical Systems. This notification indicates the device has undergone a review process to demonstrate substantial equivalence to legally marketed predicate devices.
FDA ART-Plan+ Medical Device Premarket Notification
The FDA has published a premarket notification (510(k)) for the ART-Plan+ medical device. This notification details the device's compliance with regulatory requirements for market entry. The document is part of the FDA's public database for medical device approvals.
BEAT IT! Trademark Renewal for Insect Repellents
The USPTO has renewed the trademark 'BEAT IT!' (TM87138736) for insect repellents, with the renewal effective March 22, 2026. The original filing date for this trademark was August 15, 2016.
USPTO Trademark Renewal for Dietary Supplements
The USPTO has renewed trademark application TM87126486 for dietary and nutritional supplements. The renewal is effective March 22, 2026, and continues the protection for a range of supplement products.
Nuclear Armageddon Trademark Renewal
The United States Patent and Trademark Office (USPTO) has renewed the trademark 'NUCLEAR ARMAGEDDON' (TM87133199) for dietary and nutritional supplements. The renewal is effective March 22, 2026.
AJOSTAR Trademark Renewal
The USPTO has renewed the AJOSTAR trademark (TM87131588), which covers a range of pharmaceutical and medicinal products. The renewal is effective March 22, 2026, and maintains the trademark's protection for its listed goods.
VETONE PROPOVAN CF Trademark Renewal
The United States Patent and Trademark Office (USPTO) has renewed the trademark VETONE PROPOVAN CF, originally filed on August 11, 2016. The renewal is effective March 22, 2026, and pertains to veterinary preparations for animal healthcare, specifically a propofol injection anesthetic.
USPTO Patent Application: VOCs for Cellular Communication
The USPTO has published patent application US20260079169A1, detailing a method for evaluating cancer behavior using volatile organic compounds (VOCs) detected in a mutual headspace between cancer cells and control samples. The application, filed on November 24, 2025, by inventors from institutions including Technion-Israel Institute of Technology, outlines a novel diagnostic approach.
USPTO Patent Application: Neuron Generation from Pluripotent Stem Cells
The USPTO has published a patent application (US20260079153A1) detailing methods for generating mature neurons from pluripotent stem cells. The disclosed methods involve overexpressing specific splicing factors to facilitate the study of neurodegenerative diseases and the accelerated derivation of mature neurons.
USPTO Patent Application: 3D Immunomechanical Organoid Model
The USPTO has published a patent application (US20260079151A1) for a 3D immunomechanical organoid model developed by the University of Notre Dame. This model is designed for observing myeloid cell interactions and for applications in drug screening and microgravity experiments.
USPTO Patent Application for Magnetic Separation of Biological Populations
The USPTO has published a new patent application (US20260079086A1) detailing an apparatus, system, and method for high-yield magnetic separation of biological populations. The application describes a system involving a cell engineering cassette, a fluidic pathway with entrapment features, and a translatable magnet array for separating subpopulations.
USPTO Patent Application: Orthogonal Mutations for Heterodimerization
The USPTO has published a patent application (US20260078202A1) detailing orthogonal mutations for heterodimerizing domains, particularly in antibody CH3 domains. This application, filed on April 25, 2025, by Jonathan Harry Davis and Nicholas M. Marshall, describes heterodimeric polypeptides and antibody constructs.
USPTO Patent Application: Ultrasensitive Immunoassay Method and Reagents
The USPTO has published a patent application detailing a new method and reagents for ultrasensitive detection of target molecules using reconstituted functional proteins. The invention aims to improve specificity and signal-to-noise ratios in various assay formats, including those for detecting viruses, bacteria, and proteins.
USPTO Patent Application: Pathogen Surrogates for Fresh Produce Sanitation
The USPTO has published a patent application (US20260079142A1) detailing pathogen surrogates with DNA tags for verifying sanitation systems in fresh produce processing. The application describes a method using these surrogates to mimic pathogen behavior during sanitation and subsequent DNA detection.
USPTO Patent Application for Tau Phospho Binding Antibodies
The USPTO has published a patent application (US20260079168A1) for Tau phospho binding antibodies and antigen binding fragments thereof. The application, filed on September 15, 2025, relates to methods for detecting Tau phospho (Thr217) and potential diagnostic or therapeutic uses for diseases associated with it.
USPTO Patent Application for Multivalent CLTX-CAR γδ T-cells
The USPTO has published a patent application (US20260078529A1) for multivalent CLTX-CAR γδ T-cells, which are designed for treating cancer or tumors. The application details specific T-cell compositions, pharmaceutical formulations, and methods of co-administering these cells with chemotherapeutic agents.
USPTO Patent Application: Light Emitting Element and Polycyclic Compound
The USPTO has published a patent application for a novel polycyclic compound and a light emitting element that includes it. The application, filed on November 19, 2025, aims to improve luminous efficiency in light emitting devices.
USPTO Patent Application: Heterocyclic Compound for Organic Light Emitting Devices
The USPTO has published a patent application detailing a novel heterocyclic compound for use in organic light-emitting devices (OLEDs). The application, filed by inventors from South Korea, claims improvements in driving voltage, light emission efficiency, and device lifetime.
USPTO Patent Application for Organic Optoelectronic Device Compound
The USPTO has published a patent application (US20260082808A1) detailing a new compound and composition for organic optoelectronic devices and display devices. The application was filed on September 8, 2025, and published on March 19, 2026.
USPTO Patent Application for Organic Light-Emitting Device Compound
The USPTO has published a patent application (US20260082806A1) for a new compound and an organic light-emitting device incorporating it. The application details a compound of Chemical Formula 1, which may offer low driving voltage, high light emitting efficiency, or a long service life.
USPTO Patent Application: Organic Electroluminescent Materials and Devices
The USPTO has published a patent application by Universal Display Corporation for organic electroluminescent materials and devices. The application details organometallic compounds, formulations, and organic light emitting devices (OLEDs) utilizing these compounds.
USPTO Patent Application for Anti-CD38 Antibodies
The USPTO has published a patent application (US20260078199A1) for anti-CD38 antibodies, therapeutics, and diagnostics. The application, filed on July 14, 2025, details methods for treating autoimmune diseases and diagnostic assays.
Carboxyalkyl Chitosan Patent Application
The USPTO has published a patent application (US20260078203A1) for a carboxyalkyl chitosan. The application details compositions, manufacturing processes, and therapeutic applications in areas such as rheumatology, ophthalmology, and dermatology. The filing date was November 26, 2025.
Anti-PTK7 Antibody Patent Application
The USPTO has published a patent application (US20260078201A1) for an anti-PTK7 antibody. The antibody is described as inhibiting angiogenesis, tumor growth, and cancer, with potential therapeutic applications for angiogenesis-related diseases and PTK7-positive cancers.
USPTO Patent Application: Systems for Targeting Cancer Cells
The USPTO has published a new patent application, US20260078200A1, detailing systems and methods for targeting cancer cells using genetically modified immune cells. The application describes novel polypeptides and their use in killing target cancer cells.
USPTO Patent Application: Predicting Disease State by Analyzing cfDNA Fragments
The USPTO has published a patent application (US20260080975A1) filed by Foundation Medicine, Inc. The application describes methods for predicting disease states by analyzing cell-free DNA (cfDNA) fragments. This is a routine publication of a patent application.
USPTO Patent Application: T cell isolation methods
The USPTO has published patent application US20260079159A1 detailing methods for isolating and expanding specific types of T cells (CD127lo/− regulatory T cells) for potential use in treating immune system disorders. The application was filed on September 12, 2025.
USPTO Patent Application: Sjögren's Syndrome Detection and Treatment
The USPTO has published a patent application detailing methods for detecting and treating Sjögren's syndrome using salivary exosomes. The application, filed by inventors from various institutions, outlines novel diagnostic and therapeutic approaches for the autoimmune disease.
USPTO Patent Application: HRD Cancer Classification and Treatment
The USPTO has published a patent application from Foundation Medicine, Inc. detailing systems and methods for classifying and treating homologous repair deficiency (HRD) cancers. The application describes models for identifying HRD-positive tumors and suggests combination therapies, such as FOLFIRINOX, for treatment.
USPTO Patent Application: Pyramidal Meditation Structure Device
The USPTO has published a patent application for a pyramidal meditation structure device. The application, filed by Rein Daloul, describes a structure with vertical beams, walls, an entrance, and integrated pipes with crystals intended to impart healing energy during meditation.